Abstract: Disclosed are a catalytic method and system for producing aromatic hydrocarbons from aliphatic hydrocarbons or light naphtha. In an aspect, the process comprises adding a diluent comprising a heavy aromatic hydrocarbon (for example, C7-C9+) to a reactor feedstock comprising aliphatic hydrocarbons (for example, C6-C8) or light naphtha to form a reactor feed stream, such that the heat capacity of reactor feed stream is higher than the heat capacity of feedstock. The reactor feed stream is heated and contacting with a catalyst under conditions sufficient to aromatize at least a portion of the aliphatic hydrocarbons and form a product stream comprising a primary aromatic hydrocarbon product and a heavy aromatic hydrocarbon product. In an aspect, the diluent can comprise a heavy aromatic hydrocarbon having at least one carbon atom more than the primary aromatic hydrocarbon product.

Abstract: Aspects of the invention relate to producing olefins by oxidative dehydrogenation cocracking of a hydrocarbon feed. In one embodiment, the method includes oxidative cocracking a hydrocarbon feed comprised of at least one alkane having a carbon chain of five or more and at least one alkane having a carbon chain of four or less by contacting the hydrocarbon feed with a metal oxide, such that the cracking of the at least one alkane having a carbon chain of four or less produces olefins and is exothermic, and the cracking of the at least one alkane having a carbon chain of five or more produces olefins and is endothermic. The method further includes utilizing the energy produced from the exothermic cracking of the alkane having a carbon chain of four or less for the endothermic cracking of the alkane having a carbon chain of five or more, and collecting the product.

Abstract: The present invention discloses an improved process for the conversion of alkanes to alkenes in the presence of a recyclable mixed oxide and perovskite catalysts with high yield.

Abstract: The invention provides processes for the preparation of HU-910, which are scalable to industrial purposes, using safer reagents and having high yield and pure product and a crystalline structure of HU-910, which is a unique product thereof.

Abstract: The invention is directed to a method for the manufacture of bisphenol A, and to bisphenol A/phenol adduct crystals. The method of the invention comprises: a) reacting phenol and acetone in the presence of an acidic catalyst to form a reaction product comprising an initial concentration of bisphenol A and an initial concentration of impurities; b) diluting the reaction product with phenol, water and/or acetone, so as to decrease the impurity concentration to 50% by weight or less of the initial concentration of impurities, and adding bisphenol A to increase the concentration thereof in the reaction product; and thereafter c) crystallising a bisphenol A/phenol adduct from the reaction product to produce a crystallised bisphenol A product.

Abstract: The present invention relates to a method of preparing methyl tert-butyl ether including a reaction step of reacting methanol with iso-butene in the presence of an acid catalyst to generate methyl tert-butyl ether; and a purification step of purify the reaction product obtained by the reaction step by introducing the reaction product into a reaction distillation column including a packing stage containing an acid catalyst, wherein a flow ratio of a recycle to a fresh feed is different per the volume of each reactor. Accordingly, the amount of unreacted iso-butene and the amount of impurities included in the reactor may be reduced, resulting in reduction of the amount of thermal energy used in a reaction distillation column.

Abstract: Disclosed are methods and systems of producing acetic acid and hydrogen from a two carbon (C2) alcohol source, the method comprising (a) obtaining a homogeneous aqueous solution comprising a C2 alcohol source and an organoruthenium (II) halide catalyst; and (b) subjecting the homogeneous aqueous solution to conditions suitable to produce a product stream comprising acetic acid and hydrogen.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: Methods and compositions comprising an emulsion or a microemulsion for use treating an oil and/or gas well are provided. In some embodiments, the emulsion or the microemulsion comprises an aqueous phase, a solvent, a surfactant comprising alkyl polyglycoside, an alcohol, and, optionally, one or more additives.

Abstract: The present disclosure relates to an aromatic amine derivative represented by general formula (I). The aromatic amine derivative has fluorescence emission at a short light emission wavelength, and the light-emission spectrum of the aromatic amine derivative has a narrow half-peak width, and accordingly, the material has deep-blue fluorescence emission and has a very-high light emission efficiency. An organic electroluminescent component prepared by using the aromatic amine derivative has deep-blue color coordinates, a high light emission efficiency and a long life-span.

Abstract: Provided are methods for making and using chiral, non-racemic protected organoboronic acids, including pinene-derived iminodiacetic acid (PIDA) boronates, to direct and enable stereoselective synthesis of organic molecules. Also provided are methods for purifying PIDA boronates from solution. Also provided are methods for deprotection of boronic acids from their PIDA ligands. The purification and deprotection methods may be used in conjunction with methods for coupling or otherwise reacting boronic acids. Iterative cycles of deprotection, coupling, and purification can be performed to synthesize chiral, non-racemic compounds. The methods are suitable for use in an automated chemical synthesis process. Also provided is an automated small molecule synthesizer apparatus for performing automated stereoselective synthesis of chiral, non-racemic small molecules using iterative cycles of deprotection, coupling, and purification.

Abstract: Disclosed are cyclopentene compounds for use as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-carbon substituted 4-aminocyclopent-1-ene-carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, and hepatocellular carcinoma (HCC).

Abstract: A method for producing N-(?-hydroxyethyl)formamide which comprises reacting formamide with acetaldehyde in a solvent in the presence of a basic catalyst in a reaction vessel, precipitating the obtained N-(?-hydroxyethyl)formamide in the reaction vessel, and collecting the precipitated N-(?-hydroxyethyl)formamide from the reaction vessel. The production of N-(?-hydroxyethyl)formamide is conducted multiple times using the same reaction vessel so that an (n+1)th reaction is conducted in the reaction vessel in which crystals of the N-(?-hydroxyethyl)formamide obtained in the n-th reaction are present (n is a natural number).

Abstract: Provided herein are crystalline forms of (((((1r, 3R, 5S, 7r)-3, 5-dimethyladamantan-1-yl)carbamoyl) oxy) methyl benzoate (Compound (I)): Also provided are compositions comprising the crystalline forms of Compound (I), processes of manufacture and methods of using the crystalline forms of Compound (I).

Abstract: This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

Abstract: The present invention provides, inter alia, a compound according to formula (I): Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for regulating GPX4 in a cell and methods for inducing ferroptosis in a cell.

Abstract: The present application relates to a method for preparing L-methionine crystals with an improved bulk density. As the L-methionine crystals prepared according to the method for preparing L-methionine crystals of the present application may have a bulk density of up to 800 g/L, the L-methionine crystals are expected to reduce storage and transport costs of L-methionine powder and improve working conditions due to improved fluidity of the powder.

Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

Abstract: Described are a salt and a resist composition capable of producing a resist pattern with satisfactory line edge roughness (LER). The salt is represented by formula (I): In formula (I), R1, R2, R3, R4 and R5 each independently represent a halogen atom or a perfluoroalkyl group having 1 to 6 carbon atoms, R6, R7 and R8 each independently represent a halogen atom, a hydroxy group, a fluorinated alkyl group having 1 to 6 carbon atoms or an alkyl group having 1 to 12 carbon atoms, and —CH2— included in the alkyl group may be replaced by —O— or —CO—, m5 represents an integer of 1 to 5, m6 represents an integer of 0 to 3, m7 represents an integer of 0 to 3, m8 represents an integer of 0 to 4, and AI? represents an organic anion.

Abstract: The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol --- represents a single or a double bond; and R1, R2, and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(?)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Abstract: The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies.

Abstract: Provided herein are compounds useful as imaging agents. Exemplary compounds provided herein are useful as myeloperoxidase imaging agents using positron emission tomography or fluorescence imaging techniques. Methods for preparing the compounds provided herein and diagnostic methods using radiolabeled and unlabeled compounds are also provided.

Abstract: A method for producing a reactive intermediate composition, including: reacting a substituted phthalic anhydride of the formula (I) with a diamine of the formula H2N—R—NH2 in the presence of an aromatic dianhydride in an amount of 10 to 50 mole percent based on the total moles of anhydride functionality in the reaction; wherein the reacting is conducted in an aprotic solvent in a reactor, under conditions effective to produce the reactive intermediate composition; and wherein X comprises a halogen or a nitro group, and R comprises a C6-36 aromatic hydrocarbon group or a halogenated derivative thereof, a straight or branched chain C2-20 alkylene or a halogenated derivative thereof, or a C3-8 cycloalkylene or a halogenated derivative thereof.

Abstract: The present invention provides an improved process for the preparation of N-protected ((3S,4R)-4-(4-fluorophenyl)piperidin-3-yl)methanol (compound (A)) and further its transformation to Paroxetine and its pharmaceutically acceptable salts. The process comprises reaction of compound (II) with amido-malonate compound (C) in the presence of a chiral catalyst and optionally a dehydrating agent to obtain compound (B); followed by reduction of (B) in the presence of a reducing agent to provide compound (A).

Abstract: Disclosed are small molecule antagonists of ?4?7 integrin, and methods of using them to treat a number of specific diseases or conditions.

Abstract: This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

Abstract: This invention relates to a process for the preparation of Form B of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. Also disclosed herein is Form B of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide, or pharmaceutical compositions thereof, obtainable by the process described herein.

Abstract: The invention relates to a compound of formula (I), wherein: A1 and A2 represent, independently of one another, a binding group comprising at least one nitrogen atom; Q1 and Q2 represent, independently of one another, a linkage group; and x is an integer between 2 and 6, preferably between 3 and 6. The invention also relates to a rubber composition comprising said compound.

Abstract: An object of the present invention is to provide a novel method capable of producing rosuvastatin calcium and intermediates therefor efficiently, inexpensively and with high purity. The present invention provides a method of efficiently producing rosuvastatin calcium and intermediates therefor having a high purity at an industrial scale, without using an extremely low temperature reaction or a special asymmetric catalyst.

Abstract: Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.

Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.

Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.

Abstract: Provided are methods of treating and/or preventing dermatological disorders. Provided are methods of reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPA1 and/or TRPV4 inhibitor. Further provided are compositions including a TRPA1 and/or TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application.

Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.

Abstract: The integrated processes herein provide improved carbon efficiency for processes based on coal or biomass gasification or steam methane reforming. Provided are also ethylene oxide carbonylation products such as beta-propiolactone and succinic anhydride having a bio-based content between 0% and 100%, and methods for producing and analyzing the same.

Abstract: Disclosed are benzoheterocyclic alkylamine compounds, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a preparation method thereof, and use of the same in the manufacture of an antibacterial drug as an inhibitor of staphyloxanthin synthesis in Staphylococcus aureus.

Abstract: Provided herein are methods for protecting cannabinoids, typically in medicinal compositions, from heat-, sunlight- or artificial-light-induced degradation, and oxidative degradation due to contact with ambient air/oxygen. Also provided are methods for extending the shelf life, stability, and long term viability and efficacy of cannabis- and cannabinoid-containing medicinal compositions. Said cannabinoids are protected by providing the one or more cannabinoids in a composition comprising at least one non-ionic surfactant and at least one polyol.

Abstract: A method for producing a compound, such as 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate, and a novel intermediate suitable for the method, whereby the compound can be stably supplied with a high total reaction yield, by changing the starting material and improving the metathesis reaction, asymmetric reduction reaction and the like.

Abstract: The present invention relates to a method for selectively separating propylene carbonate by adding water to reaction products comprising a polyether carbonate polyol and propylene carbonate, which are generated from a polymerization reaction of propylene oxide and carbon dioxide under a double metal cyanide (DMC) catalyst, wherein an economical and effective separation of propylene carbonate can be achieved.

Abstract: Methods for preparing compounds of formula (I) Wherein R1 to R5 and A1 to A4 are as defined in the application.

Abstract: The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: The present invention concerns 4-amino-2-pyrido-bicyclic pyrimidines as type II topoisomerase inhibitors and use thereof as medicaments especially in the treatment of cancer. The invention also provides a method for the manufacture of 4-amino-2-pyrido bicyclic pyrimidines.

Abstract: Chiral acetyl-protected aminoethyl quinoline (APAQ), pyridine and imazoline ligands are disclosed that enable Pd (II)-catalyzed enantioselective arylation or heteroarylation of ubiquitous prochiral ?-methylene C—H bonds of aliphatic amides offers an alternative disconnection for constructing ?-chiral centers. Systematic tuning of the ligand structure reveals that a six-membered instead of a five-membered chelation of these types of ligands with the Pd(II) is important for accelerating the C(sp3)-H activation thereby achieving enantioselectivity for quinoline and pyridine ligands.

Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

Abstract: The present invention relates to new profluorophores and conjugates thereof and their use for the detection of target molecule in a sample, in particular nucleic acid target molecules. The invention relates to new profluorophores and new fluorophores and methods of use thereof particularly useful in the fields of diagnostics and quality control.

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.